Morgan Stanley Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $915
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison maintains an Overweight rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and raises the price target from $912 to $915.
October 11, 2023 | 2:44 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley maintains an Overweight rating on Regeneron Pharmaceuticals and raises the price target from $912 to $915, which could positively impact the stock.
The raised price target by Morgan Stanley indicates a positive outlook for Regeneron Pharmaceuticals. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100